Envudeucitinib Misses Overall SLE Endpoints; Biomarker Subgroup Separates
Alumis reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet its Week-48 BICLA primary endpoint or key secondary endpoints in the overall population. BICLA response was…
